Latin America's clinical research narrative is shifting from announcement to execution.
first-in-human · clinical research
bioaccess® | Global Trial Accelerators™ | Fast-Tracking First-in-Human Trials, Anywhere
Read the full newsletter online here.
Latin America's clinical research narrative is shifting from announcement to execution. Mexico has moved its 30-day authorization pathway into operational reality, Brazil's anuência queue is now producing material volume signals, Colombia's device-trial transparency picture is complete, and Argentina is layering harmonization on top of investment scale. The story of 2026 is no longer whether LATAM can reform -- it's how fast each market can deliver.
Take a closer look at how LATAM's clinical research architecture is moving from reform announcements to operational delivery. 👇
Mexico's clinical research environment may be undergoing its most significant transformation in years. COFEPRIS has confirmed that its new digital platform will launch in July, alongside the operational rollout of the agency's 30-day clinical trial authorization pathway. The changes go well beyond timeline reductions: the agency is consolidating processes, reducing administrative requirements, and implementing parallel reviews between COFEPRIS and hospital ethics committees.
Perhaps the most consequential development is the adoption of a mutual-recognition principle for foreign regulatory clearances. Rather than repeating reviews from the beginning, COFEPRIS will be able to rely on prior assessments from trusted regulatory authorities. Taken together, the reforms position Mexico as a far more competitive destination for clinical research than it was only a year ago.
Why It Matters: Mexico's announcement-to-execution gap has now closed. Sponsors evaluating LATAM filing sequences should re-rank Mexico as a front-tier option for 2026-2027 programs, particularly where prior FDA, Health Canada, or PMDA clearance allows reliance under the new abbreviated pathway.
ANVISA's publication of Resolução-RE No. 2.316 provides one of the clearest indicators yet that Brazil's updated clinical research framework is operating at scale. The resolution covers clinical research dossier reviews and protocol modifications involving 14 investigational products from multinational sponsors including Roche, Novartis, Sanofi, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Astellas, and GlaxoSmithKline.
Equally notable is the concentration of major CROs involved in the listed programs, including Medpace, IQVIA, PPD, and Parexel. Their presence offers a glimpse into how multinational development programs are moving through ANVISA's revised regulatory structure. Rather than a single headline-grabbing approval, the resolution reflects something more important: growing evidence that Brazil's clinical research pipeline is moving through the system in meaningful volume.
Bottom Line: ANVISA's anuência queue under Lei 14.874/2024 is now generating measurable throughput. For LATAM-native CROs, this is both opportunity and warning: throughput attracts multinational competition, but it also confirms Brazil as a strategic market that can support volume-based business cases for early-phase work.
INVIMA has released its registry of approved medical device clinical studies covering the period from 2021 through February 2025. The database includes study protocols, investigational products, sponsors, ethics committees, participating institutions, and responsible investigators. More importantly, it complements the regulator's recently published registry of non-approved device studies.
Together, the two datasets create one of the most comprehensive publicly available medical device clinical research records published by a regulator in Latin America. The publication opens the door to a deeper understanding of approval patterns, study categories, and potential areas of regulatory friction within Colombia's device-trial ecosystem.
What to Focus On: Sponsors evaluating Colombian device programs should commission a combined-registry analysis -- approved versus non-approved -- by device category. The comparative pattern will reveal which device classes face the highest regulatory friction in Colombia, an analytical capability that did not exist in LATAM markets six months ago.
bioaccess® is the world's First-in-Human CRO built for U.S. regulatory anchoring and Latin American execution. We help MedTech, Biopharma, and Radiopharma innovators compress timelines, reduce costs, and generate FDA/EMA-ready evidence -- across seven active LATAM jurisdictions.
Schedule your first-in-human trial consultation at bioaccessla.com.
Colombia's presidential runoff was held on June 21, with results bringing renewed attention to the country's future policy direction. The two candidates have represented materially different approaches to health-system governance, regulatory modernization, and the future trajectory of reforms affecting research oversight. With inauguration scheduled for August 7, the new administration will assume responsibility for shaping the next phase of INVIMA modernization, the future of PL 191, and broader public-sector research policy.
For sponsors active in Colombia, the relevant question is no longer the outcome of the vote -- it is what the incoming administration prioritizes, and how quickly. Continuity structures such as INVIMA's Mesa Nacional de Investigación Clínica may prove to be the most durable bridges across the political transition.
Why It Matters: Sponsors with active or planned Colombian programs should focus on Mesa Nacional work products through July and August. Governance structures that produce deliverables before the August 7 inauguration are likely to survive the administrative transition; those that don't are at risk of being deprioritized.
ANMAT highlighted its participation in the recent International Council for Harmonisation (ICH) plenary meeting held in Rio de Janeiro, reinforcing Argentina's commitment to global regulatory alignment. The development may appear procedural, but it carries broader significance. Continued engagement with ICH supports Argentina's efforts to align with internationally recognized regulatory standards and strengthens confidence in the country's evolving clinical research framework.
The participation also arrives as stakeholders continue monitoring implementation of Argentina's 62-day authorization pathway. While empirical performance data remains limited, ANMAT's growing presence within international regulatory forums reinforces its long-term harmonization strategy.
Bottom Line: Argentina's regulatory positioning is becoming more credible internationally even as the 62-day cap remains empirically unvalidated. Sponsors should treat ICH alignment as a leading indicator that ANMAT's reform direction is durable -- even if execution data has yet to follow.
Argentina continues to strengthen its position as one of Latin America's most active clinical research markets, supported by reports of an estimated US$8 billion commitment to research and development activity. The investment narrative arrives alongside broader regulatory reforms, including ANMAT's 62-day authorization framework and the agency's continued engagement with international harmonization initiatives.
Together, these developments point to a market seeking to combine regulatory modernization with long-term ecosystem growth. For MedTech and Biopharma innovators evaluating first-in-human and early-phase programs, Argentina's story is increasingly about scale. The combination of regulatory reform, international alignment, and sustained investment suggests the country intends to remain a significant player in global clinical research for years to come.
What to Focus On: Sponsors should monitor whether the announced R&D commitment translates into infrastructure investments at Argentine sites, particularly in oncology, immunology, and metabolism -- the three therapeutic areas where ANMAT's 2025 dataset showed the strongest growth.
bioaccess® | Fast-Tracking First-in-Human Trials, Anywhere.
Follow us on LinkedIn | Subscribe to Global Trial Accelerators™
← All Global Trial Accelerators editions · Contact bioaccess®